STAT+: In early trial, drug appears to reduce harmful protein buildup in heart
STAT
MAY 20, 2023
An early-stage drug for a heart disease called ATTR-CM showed potential to reverse disease progression, opening up a new way of attacking the condition as existing drugs have been designed to only slow or stall the disease. In a small Phase 1 trial, the drug, a monoclonal antibody named NI006, appeared to reduce harmful protein buildup in the heart based on imaging, according to the study , published Saturday in the New England Journal of Medicine.
Let's personalize your content